Literature DB >> 4064256

Depletion of O6-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N'-nitro-N-nitrosoguanidine.

J Domoradzki, A E Pegg, M E Dolan, V M Maher, J J McCormick.   

Abstract

We showed previously that resistance of a series of human fibroblast cell lines to the cytotoxic and mutagenic effects of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) is highly correlated with their level of O6-methylguanine-DNA-methyltransferase (MT) activity. In the present study, MT activity in normal fibroblasts was decreased to between 40 and 20% of the constitutive level by 15 or 24 h exposure of the cells to exogenous O6-methylguanine (O6-MeG). MT-depleted and non-depleted populations were then challenged with various doses of MNNG and assayed for cytotoxicity and mutagenicity. At every dose the frequency of 6-thioguanine resistant cells induced by MNNG was higher in the MT-depleted populations than in the controls. Since the MT activity in these cells does not remove methyl from the O4 position of thymine, these results strongly support the hypothesis that O6-methylguanine is the principal mutagenic lesion induced by MNNG. Cells with decreased levels of MT were not significantly more sensitive to the cytotoxic effect of MNNG. If O6-methylguanine is a potentially cytotoxic lesion, this lack of increased sensitivity may reflect the fact that regeneration of MT protein occurred rapidly enough to remove these lesions before they resulted in cell death (i.e., inability to form a clone). Consistent with this explanation is the fact that 7 h after removal of the exogenous O6-MeG, the level of MT activity had regenerated to 51% of normal; by 18 h, it was 65% of normal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064256     DOI: 10.1093/carcin/6.12.1823

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Mutagenic specificity of N-methyl-N'-nitro-N-nitrosoguanidine in the gpt gene on a chromosome of Chinese hamster ovary cells and of Escherichia coli cells.

Authors:  H Sockett; S Romac; F Hutchinson
Journal:  Mol Gen Genet       Date:  1991-06

2.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 3.  Cancer chemotherapy: new strategies for success.

Authors:  N A Berger
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Suppression of human DNA alkylation-repair defects by Escherichia coli DNA-repair genes.

Authors:  L Samson; B Derfler; E A Waldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD+ Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase.

Authors:  Jianfeng Li; Christopher A Koczor; Kate M Saville; Faisal Hayat; Alison Beiser; Steven McClellan; Marie E Migaud; Robert W Sobol
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

6.  Complementation of sensitivity to alkylating agents in Escherichia coli and Chinese hamster ovary cells by expression of a cloned bacterial DNA repair gene.

Authors:  H Kataoka; J Hall; P Karran
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

7.  Mechanisms of differential strain sensitivity in gastric carcinogenesis.

Authors:  J H Weisburger; R C Jones; W S Barnes; A E Pegg
Journal:  Jpn J Cancer Res       Date:  1988-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.